178 related articles for article (PubMed ID: 11721637)
1. Proteomic approaches to biomarker discovery in prostate and bladder cancers.
Adam BL; Vlahou A; Semmes OJ; Wright GL
Proteomics; 2001 Oct; 1(10):1264-70. PubMed ID: 11721637
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery.
Tanase CP; Codrici E; Popescu ID; Mihai S; Enciu AM; Necula LG; Preda A; Ismail G; Albulescu R
Oncotarget; 2017 Mar; 8(11):18497-18512. PubMed ID: 28061466
[TBL] [Abstract][Full Text] [Related]
3. Mass spectrometry-based expression profiling of clinical prostate cancer.
Wright ME; Han DK; Aebersold R
Mol Cell Proteomics; 2005 Apr; 4(4):545-54. PubMed ID: 15695425
[TBL] [Abstract][Full Text] [Related]
4. Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: Focus on Bladder Cancer.
Latosinska A; Frantzi M; Vlahou A; Mischak H
Proteomics Clin Appl; 2013 Dec; 7(11-12):779-93. PubMed ID: 23970371
[TBL] [Abstract][Full Text] [Related]
5. Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants.
Nguyen EV; Centenera MM; Moldovan M; Das R; Irani S; Vincent AD; Chan H; Horvath LG; Lynn DJ; Daly RJ; Butler LM
Mol Cell Proteomics; 2018 Aug; 17(8):1470-1486. PubMed ID: 29632047
[TBL] [Abstract][Full Text] [Related]
6. SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis.
Wright GL
Expert Rev Mol Diagn; 2002 Nov; 2(6):549-63. PubMed ID: 12465452
[TBL] [Abstract][Full Text] [Related]
7. [Capillary electrophoresis coupled to mass spectrometry for proteome analysis. An innovative diagnostic method for prostate and bladder cancer].
Wittke S; Schiffer E; Bauer HW
Urologe A; 2007 Jul; 46(7):733-9. PubMed ID: 17318473
[TBL] [Abstract][Full Text] [Related]
8. Cancer stroma proteome expression profile of superficial bladder transitional cell carcinoma and biomarker discovery.
Niu HT; Yang CM; Jiang G; Xu T; Cao YW; Zhao J; Wang XS
J Cancer Res Clin Oncol; 2011 Aug; 137(8):1273-82. PubMed ID: 21706132
[TBL] [Abstract][Full Text] [Related]
9. Proteomics for the identification of new prostate cancer biomarkers.
Ornstein DK; Tyson DR
Urol Oncol; 2006; 24(3):231-6. PubMed ID: 16678055
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology.
Fredolini C; Meani F; Luchini A; Zhou W; Russo P; Ross M; Patanarut A; Tamburro D; Gambara G; Ornstein D; Odicino F; Ragnoli M; Ravaggi A; Novelli F; Collura D; D'Urso L; Muto G; Belluco C; Pecorelli S; Liotta L; Petricoin EF
AAPS J; 2010 Dec; 12(4):504-18. PubMed ID: 20549403
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel alternative splicing biomarkers for breast cancer with LC/MS/MS and RNA-Seq.
Zhang F; Deng CK; Wang M; Deng B; Barber R; Huang G
BMC Bioinformatics; 2020 Dec; 21(Suppl 9):541. PubMed ID: 33272210
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Proteomic Analysis Identifies AHNAK (Neuroblast Differentiation-associated Protein AHNAK) as a Novel Candidate Biomarker for Bladder Urothelial Carcinoma Diagnosis by Liquid-based Cytology.
Lee H; Kim K; Woo J; Park J; Kim H; Lee KE; Kim H; Kim Y; Moon KC; Kim JY; Park IA; Shim BB; Moon JH; Han D; Ryu HS
Mol Cell Proteomics; 2018 Sep; 17(9):1788-1802. PubMed ID: 29950347
[TBL] [Abstract][Full Text] [Related]
13. Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform.
Schiffer E; Mischak H; Theodorescu D; Vlahou A
World J Urol; 2008 Feb; 26(1):67-74. PubMed ID: 18175124
[TBL] [Abstract][Full Text] [Related]
14. Comparative Tissue Proteomics of Microdissected Specimens Reveals Novel Candidate Biomarkers of Bladder Cancer.
Chen CL; Chung T; Wu CC; Ng KF; Yu JS; Tsai CH; Chang YS; Liang Y; Tsui KH; Chen YT
Mol Cell Proteomics; 2015 Sep; 14(9):2466-78. PubMed ID: 26081836
[TBL] [Abstract][Full Text] [Related]
15. The Proteome of Primary Prostate Cancer.
Iglesias-Gato D; Wikström P; Tyanova S; Lavallee C; Thysell E; Carlsson J; Hägglöf C; Cox J; Andrén O; Stattin P; Egevad L; Widmark A; Bjartell A; Collins CC; Bergh A; Geiger T; Mann M; Flores-Morales A
Eur Urol; 2016 May; 69(5):942-52. PubMed ID: 26651926
[TBL] [Abstract][Full Text] [Related]
16. Proteomic investigation of intra-tumor heterogeneity using network-based contextualization - A case study on prostate cancer.
Goh WWB; Zhao Y; Sue AC; Guo T; Wong L
J Proteomics; 2019 Aug; 206():103446. PubMed ID: 31323421
[TBL] [Abstract][Full Text] [Related]
17. Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer.
Moreira JM; Ohlsson G; Gromov P; Simon R; Sauter G; Celis JE; Gromova I
Mol Cell Proteomics; 2010 Jan; 9(1):161-77. PubMed ID: 19783793
[TBL] [Abstract][Full Text] [Related]
18. Parafilm-assisted microdissection: a sampling method for mass spectrometry-based identification of differentially expressed prostate cancer protein biomarkers.
Quanico J; Franck J; Gimeno JP; Sabbagh R; Salzet M; Day R; Fournier I
Chem Commun (Camb); 2015 Mar; 51(22):4564-7. PubMed ID: 25490716
[TBL] [Abstract][Full Text] [Related]
19. Proteomics in diagnosis of prostate cancer.
Davalieva K; Polenakovic M
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):5-36. PubMed ID: 26076772
[TBL] [Abstract][Full Text] [Related]
20. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.
Ornstein DK; Rayford W; Fusaro VA; Conrads TP; Ross SJ; Hitt BA; Wiggins WW; Veenstra TD; Liotta LA; Petricoin EF
J Urol; 2004 Oct; 172(4 Pt 1):1302-5. PubMed ID: 15371828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
